Edition:
United States

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

59.64USD
17 Nov 2017
Change (% chg)

$0.01 (+0.02%)
Prev Close
$59.63
Open
$59.64
Day's High
$60.03
Day's Low
$59.23
Volume
86,787
Avg. Vol
161,012
52-wk High
$72.66
52-wk Low
$39.25

Select another date:

Fri, Nov 17 2017

BRIEF-Agios presents updated phase 1 data from dose expansion cohort of ivosidenib

* Agios presents updated phase 1 data from dose expansion cohort of ivosidenib (AG-120) in patients with IDH1 mutant positive glioma

BRIEF-Agios reports Q3 revenue $11.4 million

* Agios Pharmaceuticals Inc - Qtrly ‍net loss per share $1.59 Source text for Eikon: Further company coverage:

BRIEF-Agios posts Q2 loss per share $1.78‍​

* Agios Pharmaceuticals Inc - ‍collaboration revenue was $11.3 million for quarter ended June 30, 2017, compared to $7.0 million for comparable period in 2016​

BRIEF-Agios Pharma says FDA approves Idhifa for treating relapsed/refractory Acute Myeloid Leukemia

* FDA grants approval of Idhifa, the first oral targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia and an IDH2 mutation Source text for Eikon: Further company coverage:

FDA approves leukemia treatment developed by Celgene, Agios

Aug 1 The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's treatment for acute myeloid leukemia (AML) patients with a specific genetic mutation.

BRIEF-Agios appoints David Scadden to the board of directors

* Agios appoints David Scadden to the board of directors Source text for Eikon: Further company coverage:

Select another date: